Videos / Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine

Description

In this Product Explainer, Infectious Disease Physician and Microbiologist Prof Paul Griffin explains the role of a recombinant respiratory syncytial virus pre-fusion F protein vaccine for prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV).

Additional resources

NCIRS FAQ: Respiratory syncytial virus (RSV) FAQs | NCIRS.
NCIRS Fact Sheet – state funding of Nirsevimab, eligibility criteria by state: State and territory nirsevimab program summary 2025.pdf

NEXT LIVE Webcast

Days

Hours

Minutes

Seconds

Expert panel – Dr Georgia Rigas & A/Prof Samantha Hocking, facilitated by Dr Angela Kwong

Weight Management in Women of Reproductive Age

Jarrod Warner & Irene Schneider

New Spirometry Standards: Key Changes for Clinical Practice

A/Prof Alberto Pinzon Charry

Food Allergy Prevention

A/Prof Daryl Cheng

Protecting Young Lungs – Paediatric Insights into RSV

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

23 June 2026

expert

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland

Product Explainer

Recombinant respiratory syncytial virus pre-fusion F protein vaccine